Cellosaurus logo
expasy logo

Cellosaurus K2 [Human melanoma] (CVCL_AT85)

[Text version]
Cell line name K2 [Human melanoma]
Accession CVCL_AT85
Resource Identification Initiative To cite this cell line use: K2 [Human melanoma] (RRID:CVCL_AT85)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Caucasian.
Microsatellite instability: Stable (MSS) (Sanger).
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: Transcriptome analysis by microarray.
Sequence variations
  • Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (Cosmic-CLP; DepMap; PubMed=15009714).
Genome ancestry Source: PubMed=30894373

Origin% genome
African0.06
Native American0
East Asian, North0
East Asian, South1.34
South Asian0.87
European, North67.62
European, South30.11
Disease Melanoma (NCIt: C3224)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Category Cancer cell line
STR profile Source(s): Cosmic-CLP

Markers:
AmelogeninX
CSF1PO10,11
D5S81811
D7S82010,11
D13S31710,13
D16S53910,13
TH017
TPOX11
vWA17

Run an STR similarity search on this cell line
Publications

PubMed=15009714; DOI=10.1046/j.0022-202X.2004.22243.x
Tsao H., Goel V., Wu H., Yang G., Haluska F.G.
Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma.
J. Invest. Dermatol. 122:337-341(2004)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010
Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Pan-cancer proteomic map of 949 human cell lines.
Cancer Cell 40:835-849.e8(2022)

Cross-references
Cell line databases/resources CLO; CLO_0037127
cancercelllines; CVCL_AT85
Cell_Model_Passport; SIDM00126
Cosmic-CLP; 1298160
DepMap; ACH-002147
LINCS_HMS; 51100
LINCS_LDP; LCL-2091
Chemistry resources GDSC; 1298160
PharmacoDB; K2_722_2019
Encyclopedic resources Wikidata; Q54899266
Gene expression databases ArrayExpress; E-MTAB-3610
Polymorphism and mutation databases Cosmic; 888867
Proteomic databases PRIDE; PXD030304
Sequence databases EGA; EGAS00001000978
Entry history
Entry creation02-May-2016
Last entry update05-Oct-2023
Version number17